Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5658739 | Gastroenterology | 2017 | 39 Pages |
Abstract
We confirmed a reduction in critical events, liver-related or not, in a prospective study of patients with HCV infection and compensated cirrhosis included in the CirVir cohort who achieved an SVR. We found an SVR to reduce overall mortality and risk of death from liver-related and non-liver-related causes. A longer follow-up evaluation is required to accurately describe and assess specific risk factors for complications in this population.
Keywords
DAAdirect antiviral agentHCV clearanceMACERBVPEG-IFNPLCIQRSBPSVRHCCα-fetoproteininterferonIFNAFPMissing dataMajor adverse cardiac eventRibavirinPrimary liver cancerUltrasonographyBacterial infectioninterquartile rangehazard ratioHCVHepatitis C virusSustained virologic responsePeg-interferonspontaneous bacterial peritonitisprognosisHepatocellular carcinoma
Related Topics
Health Sciences
Medicine and Dentistry
Gastroenterology
Authors
Pierre Nahon, Valérie Bourcier, Richard Layese, Etienne Audureau, Carole Cagnot, Patrick Marcellin, Dominique Guyader, Hélène Fontaine, Dominique Larrey, Victor De Lédinghen, Denis Ouzan, Fabien Zoulim, Dominique Roulot, Albert Tran,